{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:05:50Z","timestamp":1760954750779},"reference-count":32,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The capsular polysaccharide of<jats:italic>Neisseria meningitidis<\/jats:italic>serogroup W135 is expressed in both<jats:italic>O<\/jats:italic>-acetyl-positive (OA<jats:sup>+<\/jats:sup>) and<jats:italic>O<\/jats:italic>-acetyl-negative (OA<jats:sup>\u2212<\/jats:sup>) forms. This study investigates the impact of OA status (OA<jats:sup>+<\/jats:sup>versus OA<jats:sup>\u2212<\/jats:sup>) on serological measurements of anti-W135 immunoglobulin G (IgG) antibodies in immunized adults. W135-specific serum antibody assignments were made for 28 postimmunization sera from adults by enzyme-linked immunosorbent assay using the meningococcal standard reference serum CDC1992. The established IgG concentration in micrograms per milliliter ([IgG]\u03bcg\/ml) for CDC1992 against OA<jats:sup>+<\/jats:sup>antigen (16.2 \u03bcg\/ml) was used as a reference to assign a concentration of 10.13 \u03bcg\/ml IgG against OA<jats:sup>\u2212<\/jats:sup>antigen by cross-standardization. Overall, the IgG assignments for these sera were higher against OA<jats:sup>+<\/jats:sup>antigen (geometric mean concentration [GMC] = 7.16 \u03bcg\/ml) than against OA<jats:sup>\u2212<\/jats:sup>antigen (GMC = 2.84 \u03bcg\/ml). However, seven sera showed higher specific [IgG]\u03bcg\/ml values against the OA<jats:sup>+<\/jats:sup>antigen than against the OA<jats:sup>\u2212<\/jats:sup>antigen. These sera were also distinguished by the inability of fluid-phase OA<jats:sup>\u2212<\/jats:sup>antigen to compete for antibody binding to OA<jats:sup>+<\/jats:sup>solid-phase antigen. Although there was no overall difference in functional activity measured by complement-mediated serum bactericidal assay (SBA) against OA<jats:sup>+<\/jats:sup>and OA<jats:sup>\u2212<\/jats:sup>target bacteria (geometric mean titers of 9,642 and 9,045, respectively), three serum specimens showed a large difference in SBA antibody titers against OA<jats:sup>+<\/jats:sup>versus OA<jats:sup>\u2212<\/jats:sup>W135 target bacteria, which may reflect different epitope specificities for these sera. Our data indicate that, for some sera, the agreement in anti-OA<jats:sup>+<\/jats:sup>versus anti-OA<jats:sup>\u2212<\/jats:sup>W135 IgG assignments is serum specific and does not reflect the functional (killing) activity in vitro.<\/jats:p>","DOI":"10.1128\/cdli.12.5.586-592.2005","type":"journal-article","created":{"date-parts":[[2005,5,5]],"date-time":"2005-05-05T13:23:00Z","timestamp":1115299380000},"page":"586-592","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["Analysis of Human Serum Immunoglobulin G against<i>O<\/i>-Acetyl-Positive and<i>O<\/i>-Acetyl-Negative Serogroup W135 Meningococcal Capsular Polysaccharide"],"prefix":"10.1128","volume":"12","author":[{"given":"Peter C.","family":"Giardina","sequence":"first","affiliation":[{"name":"Department of Applied Immunology and Microbiology, Wyeth Vaccines Research, 401 Middletown Road, Pearl River, New York 10965"},{"name":"Meningococcal Reference Unit, Manchester Medical Microbiology Partnership, Health Protection Agency Northwest, Clinical Sciences Building, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Longworth","sequence":"additional","affiliation":[{"name":"Department of Applied Immunology and Microbiology, Wyeth Vaccines Research, 401 Middletown Road, Pearl River, New York 10965"},{"name":"Meningococcal Reference Unit, Manchester Medical Microbiology Partnership, Health Protection Agency Northwest, Clinical Sciences Building, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee E.","family":"Evans-Johnson","sequence":"additional","affiliation":[{"name":"Department of Applied Immunology and Microbiology, Wyeth Vaccines Research, 401 Middletown Road, Pearl River, New York 10965"},{"name":"Meningococcal Reference Unit, Manchester Medical Microbiology Partnership, Health Protection Agency Northwest, Clinical Sciences Building, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaelene L.","family":"Bessette","sequence":"additional","affiliation":[{"name":"Department of Applied Immunology and Microbiology, Wyeth Vaccines Research, 401 Middletown Road, Pearl River, New York 10965"},{"name":"Meningococcal Reference Unit, Manchester Medical Microbiology Partnership, Health Protection Agency Northwest, Clinical Sciences Building, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Applied Immunology and Microbiology, Wyeth Vaccines Research, 401 Middletown Road, Pearl River, New York 10965"},{"name":"Meningococcal Reference Unit, Manchester Medical Microbiology Partnership, Health Protection Agency Northwest, Clinical Sciences Building, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Department of Applied Immunology and Microbiology, Wyeth Vaccines Research, 401 Middletown Road, Pearl River, New York 10965"},{"name":"Meningococcal Reference Unit, Manchester Medical Microbiology Partnership, Health Protection Agency Northwest, Clinical Sciences Building, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dace","family":"Madore","sequence":"additional","affiliation":[{"name":"Department of Applied Immunology and Microbiology, Wyeth Vaccines Research, 401 Middletown Road, Pearl River, New York 10965"},{"name":"Meningococcal Reference Unit, Manchester Medical Microbiology Partnership, Health Protection Agency Northwest, Clinical Sciences Building, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Fernsten","sequence":"additional","affiliation":[{"name":"Department of Applied Immunology and Microbiology, Wyeth Vaccines Research, 401 Middletown Road, Pearl River, New York 10965"},{"name":"Meningococcal Reference Unit, Manchester Medical Microbiology Partnership, Health Protection Agency Northwest, Clinical Sciences Building, Manchester M13 9WZ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"2228","volume":"2","year":"2000","unstructured":"Apicella, M. A. 2000. Neisseria meningitidis, p. 2228-2241. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practices of infectious diseases, 5th ed., vol. 2. Churchill Livingstone, New York, N.Y.","journal-title":"Principles and practices of infectious diseases"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.59.12.4349-4356.1991"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.176.3.691-695.1994"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.7.3707-3713.2002"},{"key":"e_1_3_2_6_2","first-page":"1","volume":"54","year":"1976","unstructured":"Bhattacharjee, A. K., H. J. Jennings, C. P. Kenny, A. Martin, and I. C. Smith. 1976. Structural determination of the polysaccharide antigens of Neisseria meningitidis serogroups Y, W-135, and BO1. Can J. Biochem.54:1-8.","journal-title":"Can J. Biochem."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/S0021-9258(19)41784-5","volume":"250","year":"1975","unstructured":"Bhattacharjee, A. K., H. J. Jennings, C. P. Kenny, A. Martin, and I. C. Smith. 1975. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J. Biol. Chem.250:1926-1932.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_8_2","first-page":"289","year":"2001","unstructured":"Borrow, R., and G. M. Carlone. 2001. Serogroup B and C serum bactericidal assays, p. 289-304. In A. J. Pollard and M. C. J. Maiden (ed.), Meningococcal vaccines: methods and protocols. Humana Press, Totowa, N.J.","journal-title":"Meningococcal vaccines: methods and protocols"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1365-2958.2003.03819.x","volume":"51","year":"2004","unstructured":"Claus, H., R. Borrow, M. Achtman, G. Morelli, C. Kantelberg, E. Longworth, M. Frosch, and U. Vogel. 2004. Genetics of capsule O-acetylation in serogroup C, W-135 and Y meningococci. Mol. Microbiol.51:227-239.","journal-title":"Mol. Microbiol."},{"key":"e_1_3_2_10_2","first-page":"725","volume":"9","year":"2002","unstructured":"Elie, C. M., P. K. Holder, S. Romero-Steiner, and G. M. Carlone. 2002. Assignment of additional anticapsular antibody concentrations to the Neisseria meningitidis group A, C, Y, and W-135 meningococcal standard reference serum CDC1992. Clin. Diagn. Lab. Immunol.9:725-726.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_11_2","first-page":"1136","volume":"10","year":"2003","unstructured":"Giardina, P. C., R. E. Evans, D. J. Sikkema, D. Madore, and S. W. Hildreth. 2003. Effect of antigen coating conditions on enzyme-linked immunosorbent assay for detection of immunoglobulin G antibody to Neisseria meningitidis serogroup Y and W135 capsular polysaccharide antigens in serum. Clin. Diagn. Lab. Immunol.10:1136-1140.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/infdis\/139.1.52","volume":"139","year":"1979","unstructured":"Glode, M. P., E. B. Lewin, A. Sutton, C. T. Le, E. C. Gotschlich, and J. B. Robbins. 1979. Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers. J. Infect. Dis.139:52-59.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","year":"1969","unstructured":"Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med.129:1307-1326.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.2.2.132-137.1995"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0731-7085(02)00462-4","volume":"30","year":"2002","unstructured":"Jones, C., and X. Lemercinier. 2002. Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture. J. Pharm. Biomed. Anal.30:1233-1247.","journal-title":"J. Pharm. Biomed. Anal."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CDLI.11.1.1-5.2004","volume":"11","year":"2004","unstructured":"Joseph, H., P. Balmer, M. Bybel, T. Papa, R. Ryall, and R. Borrow. 2004. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera. Clin. Diagn. Lab. Immunol.11:1-5.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0008-6215(96)00253-4","volume":"296","year":"1996","unstructured":"Lemercinier, X., and C. Jones. 1996. Full 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production. Carbohydr. Res.296:83-96.","journal-title":"Carbohydr. Res."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.2307\/2532051"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1016\/S0021-9258(18)61992-1","volume":"246","year":"1971","unstructured":"Liu, T. Y., E. C. Gotschlich, F. T. Dunne, and E. K. Jonssen. 1971. Studies on the meningococcal polysaccharides. II. Composition and chemical properties of the group B and group C polysaccharide. J. Biol. Chem.246:4703-4712.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1016\/S0021-9258(18)62260-4","volume":"246","year":"1971","unstructured":"Liu, T. Y., E. C. Gotschlich, E. K. Jonssen, and J. R. Wysocki. 1971. Studies on the meningococcal polysaccharides. I. Composition and chemical properties of the group A polysaccharide. J. Biol. Chem.246:2849-2858.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1574-695X.2002.tb00543.x","volume":"32","year":"2002","unstructured":"Longworth, E., P. Fernsten, T. L. Mininni, U. Vogel, H. Claus, S. Gray, E. Kaczmarski, and R. Borrow. 2002. O-Acetylation status of the capsular polysaccharides of serogroup Y and W135 meningococci isolated in the UK. FEMS Immunol. Med. Microbiol.32:119-123.","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0003-2697(60)90020-8","volume":"1","year":"1960","unstructured":"Mandell, J. D., and A. D. Hershey. 1960. A fractionating column for analysis of nucleic acids. Anal. Biochem.1:66-77.","journal-title":"Anal. Biochem."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.4.2.156-167.1997"},{"key":"e_1_3_2_24_2","first-page":"151","volume":"103","year":"2000","unstructured":"Michon, F., C. H. Huang, E. K. Farley, L. Hronowski, J. Di, and P. C. Fusco. 2000. Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope. Dev. Biol.103:151-160.","journal-title":"Dev. Biol."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.7.2695-2699.2001"},{"key":"e_1_3_2_26_2","first-page":"666","volume":"20","year":"2002","unstructured":"Morley, S. L., and A. J. Pollard. 2002. Vaccine prevention of meningococcal disease, coming soon? Vaccine20:666-687.","journal-title":"Vaccine"},{"key":"e_1_3_2_27_2","unstructured":"Neter J. M. H. Kutner C. J. Nachtsheim and W. Wasserman. 1996. Applied linear regression models 3rd ed. Irwin Boston Mass."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1542\/peds.76.1.91","volume":"76","year":"1985","unstructured":"Peltola, H., A. Safary, H. Kayhty, V. Karanko, and F. E. Andre. 1985. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. Pediatrics76:91-96.","journal-title":"Pediatrics"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.4.2378-2382.2001"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev.micro.50.1.285","volume":"50","year":"1996","unstructured":"Roberts, I. S. 1996. The biochemistry and genetics of capsular polysaccharide production in bacteria. Annu. Rev. Microbiol.50:285-315.","journal-title":"Annu. Rev. Microbiol."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.8.3.616-623.2001"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.7.5.764-768.2000"},{"key":"e_1_3_2_33_2","unstructured":"World Health Organization. 1976. Requirements for meningococcal polysaccharide vaccine. Requirements for biological substances no. 23 p. 72-73 vol. 594. World Health Organization Geneva Switzerland."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CDLI.12.5.586-592.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CDLI.12.5.586-592.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T11:31:41Z","timestamp":1706182301000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CDLI.12.5.586-592.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1128\/CDLI.12.5.586-592.2005"],"URL":"https:\/\/doi.org\/10.1128\/cdli.12.5.586-592.2005","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"type":"print","value":"1556-6811"},{"type":"electronic","value":"1556-679X"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"2004-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-02-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}